Company Snapshot
- Ticker
- HOLX
- Name
- HOLX
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 16924698750.000000
- Volume
- 2,129,289
- Avg Volume (3M)
- 2,822,491
HOLX
HOLX
Last update recent
75.00
+0.17
(+0.23%)
Market Cap
16924698750.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 4100400000.000000
- EPS
- 2.50
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 0.0%
- Net Income
- 565800000.000000
- Net Margin
- 13.8%
- Payout Ratio
- 0.0%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 29.91
- Forward P/E
- None
- P/S
- 4.13
- P/B
- 3.50
- Beta
- None
- Debt / Equity
- 0.52
- Current Ratio
- 3.55
- Return on Equity
- 0.12%
- Return on Assets
- 0.06%
Technicals & Returns
- Distance vs 200 DMA
- 14.42%
- 200 DMA
- 65.55
- Distance vs 50 DMA
- 2.91%
- 50 DMA
- 72.88
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep Read more
- Name
- HOLX
- Industry
- Medical - Instruments & Supplies
- CEO
- Mr. Stephen P. MacMillan
- Employees
- 6,990
- IPO Date
- 1990-03-01
- Phone
- 508 263 2900
- Address
- None
- Website
- https://www.hologic.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Latest News
Curated headlines from premium sources.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's pr…
What Is Driving Hologic's Strength in the US Diagnostics Market?
HOLX's Diagnostics gains accelerate as U.S. molecular testing drives growth and new Panther Fusion and Genius platform approvals widen its runway.
First Trust Advisors LP Sells 2,413,872 Shares of Hologic, Inc. $HOLX
First Trust Advisors LP cut its holdings in shares of Hologic, Inc. (NASDAQ: HOLX) by 83.4% during the undefined quarter, according to the company in its most …
Blue Door Asset Management LLC Takes Position in Hologic, Inc. $HOLX
Blue Door Asset Management LLC acquired a new position in shares of Hologic, Inc. (NASDAQ: HOLX) during the second quarter, according to the company in its mos…
HOLX Stock Up 16% in 6 Months: Is it Still a Hold Heading Into 2026?
Hologic shares rise 16% in six months, with divisional strength clinical data and a go-private deal shaping the short-term outlook.
Edgestream Partners L.P. Has $1.92 Million Stock Holdings in Hologic, Inc. $HOLX
Edgestream Partners L.P. lifted its holdings in shares of Hologic, Inc. (NASDAQ: HOLX) by 75.5% during the undefined quarter, according to the company in its m…